Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

The deal includes over $200 million in upfront and near-term payments to Septerna. The move is part of Novo Nordisk’s broader strategy to expand its presence in the highly competitive obesity ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery ... The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline ...

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license agreement with Danish pharma company, Novo Nordisk NVO, for developing and ...

Under the deal, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including an upfront payment of $200 million and near-term milestone payments. SEPN is also entitled to ...

The deal includes over $200 million in upfront and near-term payments to Septerna. The move is part of Novo Nordisk’s broader strategy to expand its presence in the highly competitive obesity ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

The upfront and near-term payment, backed by milestones that could take the total value of the licensing deal to around ... scalability," he said. Novo Nordisk and Septerna will jointly carry ...

Novo Nordisk and Septerna have announced a new partnership worth ... of receiving future milestones and royalties for that asset. Also commenting on the deal, Septerna’s chief executive officer and co ...